'Strategic alternatives' loom for Pharmexa

The roiled stock market is causing some headaches at a European biotech company. Troubled by disappointing mid-stage trial data and a weak stock market, Denmark's Pharmexa is signaling that it will need to explore "strategic alternatives" as it finds itself short of the cash needed to operate under its current strategy. Pharmexa raised $18 million in a recent rights issue, far below what it had expected to earn.

"The way that the [preemption] rights were trading and the way the stock price performed during the fundraising process...we had expected more," Pharmexa CEO Jakob Schmidt told BioWorld International. "We are grateful for the money we got. In these markets, DKK90 million is still a decent amount of money. It's something to build on. Now we will take a few weeks to consider the options."

- see this release
- check out the report from BioWorld

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.